CervoMed
CervoMed's revenue fell 58.9% to $4 million in fiscal 2025. Its operating margin was −706.2%, down from −187.2% a year earlier. The diluted share count rose 12.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CervoMed does
CervoMed is a clinical-stage biotech company: it develops drugs for age-related brain disorders but has none approved for sale. Its only drug candidate, neflamapimod, is a pill that reaches the brain and blocks an enzyme called p38 alpha, which the company says drives inflammation in the brain and harms the connections between nerve cells.
Its main target is dementia with Lewy bodies (DLB), a progressive dementia with no approved treatment in the US or the European Union. CervoMed focuses on patients whose disease is not mixed with Alzheimer's, a group it believes is more treatable. In November 2025 it said it had agreed with the FDA on key parts of a planned late-stage (Phase 3) trial in DLB, which it plans to start once it has the funding. It is also testing the drug in earlier trials in a form of primary progressive aphasia (a disorder that erodes language), in recovery after stroke and, through a program funded by the UK government and charities, in ALS.
The company has no revenue from product sales. It licenses neflamapimod from Vertex, to which it may owe milestone payments and royalties if the drug succeeds, and it has received a grant from the National Institute on Aging. At the end of 2025 it had 15 full-time employees and relied on outside firms to run its trials and make the drug.
Its biggest risks, as it describes them
- It needs more money to keep developing neflamapimod and may not be able to raise it on acceptable terms.
- It depends almost entirely on one drug candidate, which may fail in trials or never be approved.
- Earlier trial results are not regulatory proof that the drug is safe or works.
- It relies on outside companies to run its trials and to make the drug, and delays there could hold it back.
- No patent covers neflamapimod's chemical makeup itself, which may leave room for competing products.
Income statement
CervoMed lost money in fiscal 2025: a net loss of $27 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 37 | 16 | 8 | 39 | 21 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | −5,920.8x | — | — | — |
| Current ratio | 12.9x | — | — | 11.1x | 4.9x |
| Quick ratio | 12.9x | — | — | 11.1x | 4.9x |
Cash flow
Projections
Project CervoMed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $3.2 million of CervoMed shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | John J AlamCEO & President, Director, 10% owner | Bought | 100,000 | $1.53 | $152,621 | Form 4 |
| Jun 11, 2026 | Joshua S BogerDirector, 10% owner | Bought | 955,414 | $3.14 | $3.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | — | 8.38 | −12.90 |
| Accruals ratio | 74.7% | 0.9% | −10.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | — | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put CervoMed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CervoMed | FY25 | −58.9% | −706.2% | — | — | — | — | |
| CAMP4 Therapeutics | FY25 | 436.5% | −1,502.4% | −852.8% | — | — | — | Compare |
| Marker Therapeutics | FY25 | −46.2% | −363.4% | — | — | — | — | Compare |
| Upstream Bio | FY25 | 20.4% | −5,618.8% | −4,675.5% | — | — | — | Compare |
| Cartesian Therapeutics | FY25 | −92.8% | −5,127.1% | −2,838.6% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | 0 | 7 | 10 | 4 |
| Revenue growth | — | — | — | — | — | — | — | — | 36.3% | −58.9% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 7 | 5 | 6 | 7 | 9 | 8 | 1 | 8 | 19 | 22 |
| Operating income | −18 | −11 | −19 | −12 | −16 | −25 | −4 | −8 | −18 | −28 |
| Net income | −18 | −1 | −18 | −12 | −14 | −24 | −6 | −2 | −16 | −27 |
| Diluted EPS (US$) | −0.53 | −0.58 | — | 134,130.18 | 1,076,639.46 | 1,946,859.00 | — | — | — | — |
| Diluted shares (millions) | 34 | 42 | 162 | — | — | — | 0 | 3 | 8 | 9 |
| Cash flow | ||||||||||
| Cash from operations | −11 | −12 | −11 | −10 | −14 | −14 | −3 | −7 | −16 | −23 |
| Capital expenditure | 0 | 0 | — | — | — | — | — | — | — | — |
| Free cash flow | −11 | −13 | — | — | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 9 | 8 | 14 | 18 | 37 | 16 | 8 | 39 | 21 |
| Debt incl. finance leases | 2 | — | — | — | — | — | — | — | — | — |
| Total assets | 18 | 26 | 18 | 24 | 28 | 38 | 4 | 10 | 43 | 23 |
| Total liabilities | 8 | 5 | 3 | 4 | 3 | 3 | 13 | 3 | 4 | 5 |
| Shareholders' equity | 9 | 21 | 16 | 20 | 25 | 35 | −33 | 7 | 39 | 18 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | −109.3% | −187.2% | −706.2% |
| Net margin | — | — | — | — | — | — | — | −30.4% | −167.3% | −673.1% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | −313.2% | — | — | — | — | — | — | — | — | — |
| Return on equity | −394.5% | −9.0% | −99.7% | −66.0% | −63.1% | −80.7% | — | — | −70.0% | −93.9% |
| Return on assets | −182.6% | −6.2% | −82.8% | −55.8% | −54.7% | −73.5% | −27.6% | −30.7% | −61.4% | −81.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |